Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on July 24, 2024, primarily to furnish its second quarter 2024 earnings press release, issued on the same date. This filing provides investors with the company's financial performance and condition for the quarter ended June 30, 2024. While the 8-K itself is brief, it serves as the official vehicle to disseminate the detailed financial results which are contained within the accompanying press release (Exhibit 99.1). Investors should refer to this press release for specific figures related to revenue, earnings, segment performance, and forward-looking guidance. The key information for investors lies within the press release, which is expected to detail the company's operational and financial achievements during the second quarter. This includes key financial metrics, commentary on business segment performance, and any updates to the company's outlook for the remainder of fiscal year 2024. The furnishing of this press release under Item 2.02 means the information is publicly available and considered by the SEC, though it does not carry the same liability as a formally "filed" document under Section 18 of the Exchange Act.
Key Highlights
- 1Boston Scientific (BSX) filed an 8-K on July 24, 2024, announcing Q2 2024 financial results.
- 2The primary content of the filing is the press release detailing Q2 2024 financial performance and condition.
- 3Investors must refer to Exhibit 99.1 (the press release) for specific financial data and operational highlights.
- 4The filing includes information for the quarter ended June 30, 2024.
- 5The press release is furnished under Item 2.02, not deemed 'filed' for Section 18 liability.
- 6The report also includes the Cover Page Interactive Data File in XBRL format.
- 7The event date for these results was July 23, 2024.